1. Home
  2. ACRS vs GMRS Comparison

ACRS vs GMRS Comparison

Compare ACRS & GMRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.33

Market Cap

529.9M

Sector

Health Care

ML Signal

HOLD

GMRS

GMR Solutions Inc. Class A Common Stock

HOLD

Current Price

$10.01

Market Cap

551.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
GMRS
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Transportation Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
551.0M
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
ACRS
GMRS
Price
$3.33
$10.01
Analyst Decision
Strong Buy
Buy
Analyst Count
12
8
Target Price
$10.18
★ $18.63
AVG Volume (30 Days)
★ 3.5M
1.1M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.01
N/A
EPS
★ N/A
N/A
Revenue
★ $1,683,000.00
N/A
Revenue This Year
N/A
$5.13
Revenue Next Year
N/A
$5.57
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.93
$9.00
52 Week High
$6.60
$15.98

Technical Indicators

Market Signals
Indicator
ACRS
GMRS
Relative Strength Index (RSI) 28.14 37.91
Support Level $3.16 $9.00
Resistance Level $3.44 $14.14
Average True Range (ATR) 0.33 0.47
MACD -0.08 0.10
Stochastic Oscillator 6.31 51.30

Price Performance

Historical Comparison
ACRS
GMRS

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About GMRS GMR Solutions Inc. Class A Common Stock

GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.

Share on Social Networks: